Strides Pharma Science Ltd Upgraded to Hold on Technical and Financial Improvements

Technical Trends Shift to Mildly Bullish

The primary catalyst for the rating upgrade is the marked improvement in Strides Pharma’s technical outlook. The technical grade has shifted from mildly bearish to mildly bullish, signalling a more favourable momentum for the stock. Key technical indicators present a mixed but improving picture. On a weekly basis, the MACD (Moving Average Convergence Divergence) is bullish, supported by bullish Bollinger Bands and a positive KST (Know Sure Thing) indicator. The Dow Theory also reflects a mildly bullish stance on both weekly and monthly timeframes.

Conversely, monthly MACD and RSI (Relative Strength Index) remain mildly bearish, and daily moving averages are mildly bearish, indicating some caution in the short term. However, the overall weekly technical momentum has improved sufficiently to warrant a more optimistic outlook. The On-Balance Volume (OBV) indicator is bullish on a monthly basis, suggesting accumulation by investors over the longer term.

These technical signals have contributed significantly to the upgrade, as the stock price has responded positively, closing at ₹980.90 on 7 April 2026, up 1.15% from the previous close of ₹969.75. The stock is trading near its 52-week high of ₹1,024.90, indicating resilience and potential for further upside.

Financial Trend: Strong Quarterly Performance but Mixed Long-Term Growth

Strides Pharma’s financial trend has been a key factor in the rating revision. The company reported a very positive quarter in Q3 FY25-26, with net profit growth surging by 133.64%. This marks the tenth consecutive quarter of positive results, underscoring consistent operational strength. Operating profit to interest coverage ratio reached a high of 5.44 times, reflecting strong earnings relative to interest expenses. Additionally, the half-yearly ROCE (Return on Capital Employed) improved to 16.05%, signalling efficient capital utilisation.

Despite these encouraging short-term results, some long-term financial metrics present a more cautious picture. Over the past five years, net sales have grown at a modest annual rate of 9.32%, while operating profit has expanded at 15.52% annually. The average ROCE over the long term stands at 7.27%, indicating moderate capital efficiency historically. Furthermore, the company’s debt servicing ability is constrained by a relatively high Debt to EBITDA ratio of 2.10 times, which could pose risks if earnings weaken.

Nevertheless, the recent financial momentum and improved profitability ratios have contributed positively to the overall assessment, supporting the Hold rating.

Valuation: Attractive Relative to Peers

Valuation metrics also played a significant role in the upgrade. Strides Pharma’s ROCE of 15.6% combined with an enterprise value to capital employed ratio of 2.4 times suggests an attractive valuation compared to its pharmaceutical peers. The stock is trading at a discount relative to the average historical valuations of its sector, providing a margin of safety for investors.

Over the last year, the stock has generated a return of 56.07%, substantially outperforming the Sensex, which declined by 1.67% over the same period. This outperformance extends over longer horizons as well, with Strides Pharma delivering 574.91% returns over three years versus 23.86% for the Sensex, and 146.47% over five years compared to 50.62% for the benchmark index. Such consistent returns highlight the stock’s ability to generate shareholder value despite some profit volatility.

However, it is noteworthy that profits have declined by 8.5% over the past year, indicating some earnings pressure that investors should monitor closely.

Quality: Mixed Fundamentals and Promoter Concerns

While the company’s recent financial results and valuation are encouraging, the quality of fundamentals remains mixed. The long-term growth rates for sales and operating profit are moderate, and the average ROCE is below what might be expected for a strong pharmaceutical player. Additionally, the company’s debt-equity ratio at 0.67 times is relatively low, which is positive, but the high Debt to EBITDA ratio tempers this advantage.

Another concern is the significant promoter share pledge, with 30.6% of promoter shares pledged. This level of pledged shares can exert downward pressure on the stock price during market downturns, adding an element of risk for investors. Such structural issues weigh on the overall quality assessment and justify a cautious stance despite recent improvements.

Stock Performance Relative to Market Benchmarks

Strides Pharma’s stock performance has been impressive relative to the broader market. The stock returned 4.60% in the past week compared to Sensex’s 3.00%, and 13.39% over the last month while the Sensex declined by 6.10%. Year-to-date, Strides Pharma has gained 8.71% whereas the Sensex has fallen 13.04%. Over the last year, the stock’s 56.07% return dwarfs the Sensex’s marginal decline of 1.67%.

Longer-term returns are even more striking, with the stock delivering nearly 575% over three years and 146% over five years, far exceeding the Sensex’s 23.86% and 50.62% respectively. This outperformance reflects the company’s ability to generate shareholder value despite sectoral and macroeconomic challenges.

Conclusion: Hold Rating Reflects Balanced Outlook

The upgrade of Strides Pharma Science Ltd’s investment rating from Sell to Hold is a reflection of improved technical indicators, strong recent financial performance, and attractive valuation metrics. The technical trend’s shift to mildly bullish, combined with a 133.64% net profit growth in the latest quarter and a robust ROCE of 16.05%, supports a more positive near-term outlook.

However, the company’s moderate long-term growth rates, average capital efficiency, and high promoter share pledge introduce caution. The stock’s valuation discount relative to peers and consistent outperformance of the Sensex provide a compelling case for investors to maintain exposure, but not to increase it aggressively at this stage.

Overall, the Hold rating with a Mojo Score of 56.0 and a Mojo Grade of Hold reflects a balanced view, recognising both the upside potential and the risks inherent in the company’s fundamentals and market environment.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today